Federal Circuit Rules For Bristol-Myers In Repligen Patent Suit

Law360, New York (July 15, 2004, 12:00 AM EDT) -- The U.S. Court of Appeals for the Federal Circuit has dealt biotech company Repligen a setback, ruling in favor of Bristol-Myers Squibb Co. in a dispute over the ownership of a patent for the immunosuppressant CTLA4-Ig.

The decision affirms a lower court’s ruling in favor of Bristol-Myers Squibb.

In August 2002, Repligen filed a patent lawsuit against Bristol-Myers Squibb in the U.S. District Court for the Eastern District of Michigan. Repligen said it is the exclusive licensee of all patent rights to CTLA4-Ig, which is owned...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.